Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q4 FY26 results · Jan–Mar 2026
Marksans Pharma reported revenue from operations of ₹856.11 crore (up 1108.4% from Q4 FY25) and net profit of ₹149.03 crore (up 1542.7% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 856.11 | 70.85 | 12x | 754.43 | +13.5% |
| Other income | 35.17 | 1.65 | 21x | 20.14 | +74.6% |
| Total income | 891.29 | 72.50 | 12x | 774.57 | +15.1% |
| Profit before tax | 200.00 | 11.61 | 17x | 150.62 | +32.8% |
| Net profit for the period | 149.03 | 9.07 | 16x | 113.69 | +31.1% |
| Attributable to shareholders of the company | 148.13 | — | — | 113.20 | +30.9% |
| EPS, basic (₹) | 3.27 | 2.00 | not comparable | 2.50 | +30.8% |
| Net margin (%) | 17.4 | 12.8 | 15.1 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 361.57 | 299.36 | +20.8% | 339.73 | +6.4% |
| Other income | 27.48 | 7.82 | +251.5% | 15.86 | +73.3% |
| Total income | 389.05 | 307.17 | +26.7% | 355.59 | +9.4% |
| Profit before tax | 124.36 | 49.90 | +149.2% | 82.12 | +51.4% |
| Net profit for the period | 91.92 | 37.59 | +144.5% | 60.91 | +50.9% |
| EPS, basic (₹) | 2.03 | 0.83 | +144.6% | 1.34 | +51.5% |
| Net margin (%) | 25.4 | 12.6 | 17.9 |
Consolidated
- Filed with BSE
- 26 May 2026, 16:35 IST
- Board meeting
- 26 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 May 2026, 16:35 IST
- Board meeting
- 26 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE